Toggle light / dark theme

After successfully transplanting the first 3D-printed cornea in an animal, North Carolina company Precise Bio has recently announced the launch of a dedicated business for creating marketable, 3D-printed products for human eyes. Founded by scientists from the Wake Forest Institute of Regenerative Medicine, this company is developing bio-fabrication printers that can restore cells, tissues, and organs. Their proprietary technology, a 4D bio-printing platform, is said to resolve existing limitations presented by other bioprinters to enable more complex tissues to be engineered for transplants and treatments. By focusing on developing marketable products for the eye, the company aims to achieve rapid advancement in its field and move to overhaul the whole organ transplant system.

When a cornea is damaged by disease or injury, a replacement is often needed to restore vision. Transplant surgery using donated corneas is an available solution, however, it relies on a deceased donor. While the waiting list in the United States is nearly non-existent, other countries require longer wait times, some over a year, before one is available. The Eye Bank Association of America estimates that around 10 million people suffer from corneal blindness that could potentially be restored via transplant surgery. An artificially manufactured cornea would overcome supply limitations while also contributing to the knowledge base to develop more complex organs such as hearts and livers.

Read more

Stem cell research firm Celprogen Inc. has been working on something quite exciting for some time now, which has remained largely under the radar until very recently. The California-based company announced it has successfully 3D printed a human brain organelle using brain stem cells. The bioprinted brain could have applications in studying neurological diseases.

More than just announcing the bioprinted brain organelle, Celprogen has also used the brain to study the “role of Microglia activation and deactivation in neurological diseases.” Through this research and experimentation, the company says it has identified and characterized 11 lead compounds that could be potential drug candidates for diseases such as Alzheimer’s, Parkinson’s and Glioblastoma.

Read more

My new article just out: The transhuman future of Quantum Archaeology & living forever is complicated, but it could still be funded by Christians if they rallied around resurrecting Jesus with 3D Bioprinting and Super Computers:

Read more

When skeletal defects are unable to heal on their own, bone tissue engineering (BTE), a developing field in orthopedics can combine materials science, tissue engineering and regenerative medicine to facilitate bone repair. Materials scientists aim to engineer an ideal biomaterial that can mimic natural bone with cost-effective manufacturing techniques to provide a framework that offers support and biodegrades as new bone forms. Since applications in BTE to restore large bone defects are yet to cross over from the laboratory bench to clinical practice, the field is active with burgeoning research efforts and pioneering technology.

Cost-effective three-dimensional (3D) printing (additive manufacturing) combines economical techniques to create scaffolds with bioinks. Bioengineers at the Pennsylvania State University recently developed a composite ink made of three materials to 3D print porous, -like constructs. The core materials, polycaprolactone (PCL) and poly (D, L-lactic-co-glycolide) acid (PLGA), are two of the most commonly used synthetic, biocompatible biomaterials in BTE. Now published in the Journal of Materials Research, the materials showed biologically favorable interactions in the laboratory, followed by positive outcomes of in an animal model in vivo.

Since bone is a complex structure, Moncal et al. developed a bioink made of biocompatible PCL, PLGA and hydroxyapatite (HAps) particles, combining the properties of bone-like mechanical strength, biodegradation and guided reparative growth (osteoconduction) for assisted natural bone repair. They then engineered a new custom-designed mechanical extrusion system, which was mounted on the Multi-Arm Bioprinter (MABP), previously developed by the same group, to manufacture the 3D constructs.

Read more

3D bioprinting company Allevi has teamed up with California-based 3D printing and space technology firm Made In Space to develop the Allevi ZeroG – the first 3D bioprinter capable of working in low-gravity conditions.

Allevi (formerly BioBots) was founded in 2014 by University of Pennsylvania graduates Ricardo Solorzano and Daniel Cabrera. At the time, the ambitious duo set out to develop an accessible desktop bioprinting system which could be used for a wide variety of research and educational applications.

Read more

The next phase of a NASA sponsored mission to 3D print human organs and tissues in space will launch in February 2019. A 3D BioFabrication Facility (BFF) developed by nScrypt and Techshot and destined for the International Space Station (ISS) will form part of the cargo of SpaceX CRS-17.

3D printing in zero gravity

nScrypt is based in Orlando, Florida and is a manufacturer of industrial micro-dispensing and 3D printing systems. The company is spin out of Sciperio Inc who, under a DARPA contact, developed an award winning bioprinter in 2003.

Read more

3D bioprinting is a process for patterning and assembling complex functional living architectures in a gradient fashion. Generally, 3D bioprinting utilizes the layer-by-layer method to deposit materials known as bioinks to create tissue-like structures. Several 3D bioprinting techniques have been developed over the last decade, for example, magnetic bioprinting, a method that employs biocompatible magnetic nanoparticles to print cells into 3D structures.

But now a Russian research team has developed a new method of bioprinting that allows to create 3D biological objects without the use of layer-by-layer approach and magnetic labels. The new method, which involves magnetic levitation research in conditions of microgravity, was conducted by the 3D Bioprinting Solutions company in collaboration with other Russian and foreign scientists, including the Joint Institute for High Temperatures of the Russian Academy of Sciences (JIHT RAS).

Read more

Erik Gatenholm is Co-Founder and CEO here at CELLINK. In 2017, he founded CELLINK to revolutionize the way that we conduct medical research worldwide. He led a workshop at the C2 Montreal conference called “Need a tissue, Bioprinting is the next Medical Revolution”

At C2 Montreal – There was a presentation on bioprinting and Cellink technology. Then there was an activity where people in groups looked at a sample of bioprinted tissue and people worked on exercises of what people thought was possible or preposterous in the future.

There was a forecast of increased tissue engineering enhanced plastic surgery.

Read more